**Table S1. Adjusted associations of EOPC with mortality in subgroup analyses**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Variables** |  | | **Overall survival (OS)** | | | **Cancer-specific survival (CSS)** | | | |
| **Median OS, EOPC, mo (IQR)** | **Median OS, AOPC mo (IQR)** | | **Adjusted**  ***P*-value** | **Adjusted**  **HR (95% CI)** | **Median CSS, EOPC, mo (IQR)** | **Median CSS, AOPC, mo (IQR)** | **Adjusted**  ***P*-value** | **Adjusted**  **HR (95% CI)** |
| Adjuvant chemotherapy  No  Yes | 35 (16-67)  55 (31-/) | 26 (18-48)  30 (19-85) | | 0.249  **0.091** | 0.763 (0.481-1.209)  0.574 (0.301-1.092) | 36 (21-67)  55 (37-/) | 28 (18-48)  30 (19-85) | 0.208  **0.042** | 0.736 (0.457-1.186)  0.496 (0.253-0.974) |
| Adjuvant radiotherapy  No  Yes | 39 (21-76)  44 (34-48) | 34 (20-55)  20 (15-33) | | 0.132  0.101 | 0.735 (0.493-1.097)  0.401 (0.134-1.197) | 50 (22-/)  44 (34-48) | 34 (20-59)  20 (15-33) | 0.069  0.101 | 0.678 (0.447-1.030)  0.401 (0.134-1.197) |
| N classification  N0  N1  N2 | 52 (29-/)  35 (19-67)  31 (17-48) | 35 (20-/)  30 (19-40)  26 (16-44) | | 0.124  0.351  0.560 | 0.629 (0.349-1.136)  0.748 (0.406-1.377)  0.788 (0.354-1.754) | 58 (34-/)  35 (19-67)  31 (22-48) | 38 (20-/)  30 (19-40)  26 (16-44) | 0.104  0.235  0.448 | 0.594 (0.317-1.113)  0.684 (0.365-1.280)  0.728 (0.321-1.651) |
| TNM staging system  I  II  III | NR (34-/)  39 (21-67)  41 (18-50) | 48 (24-/)  26 (16-40)  26 (17-44) | | 0.525  **0.042**  0.471 | 0.764 (0.333-1.754)  0.566 (0.327-0.980)  0.792 (0.420-1.493) | NR (34-/)  53 (26-/)  41 (22-50) | 48 (25-/)  26 (16-40)  26 (17-44) | 0.729  **0.015**  0.284 | 0.860 (0.366-2.021)  0.489 (0.276-0.868)  0.699 (0.363-1.345) |

AOPC, average-onset pancreatic cancer; CI, confidence interval; EOPC, early-onset pancreatic cancer; HR, hazard ratio; IQR, interquartile range; NR, not reached; TNM, tumor, lymph node, metastasis.